Open AccessMass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic
Author(s) -
Vicente Aldasoro Cáceres,
María Laíño Piñeiro,
Berta Ibáñez,
Mónica Enguita-Germán
Publication year - 2022
Publication title -
journal of clinical rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.615
H-Index - 50
eISSN - 1536-7355
pISSN - 1076-1608
DOI - 10.1097/rhu.0000000000001862
Subject(s) - tocilizumab , medicine , rheumatoid arthritis , polymyalgia rheumatica , rheumatology , adverse effect , arthritis , giant cell arteritis , disease , vasculitis
With the arrival of the SARS-CoV-2 pandemic in 2020, it was proposed to make the change from intravenous (IV) tocilizumab (TCZ) to its subcutaneous formulation, in order to avoid rheumatological patients having to go to the day hospital and guarantee enough IV TCZ for those critical patients with COVID who needed it. The aim of this study was to describe the rate and reasons for switching back to IV TCZ from subcutaneous TCZ.